2024 IAS-USA Guidelines Virtual Update: Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
You must Login or Create Account in order to register for this event
Co-Chairs
Panelists
Brenda E. Crabtree-Ramirez, MD
December 12, 2024
1:00 PM - 5:30 PM ET; 10:00 AM - 2:30 PM PTLast Modified:
Program Description
Join us for a timely and highly relevant half-day virtual course designed to bring you up to speed on the latest guidelines in antiretroviral strategies for the treatment and prevention of HIV infection in adults. This course will review the newly released Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel, published online by the Journal of the American Medical Association (JAMA) on December 1, 2024. This course will focus on the new recommendations and practical applications of the updated guidelines in clinical practice through case-based learning and insightful panel discussions led by the experts who served on the guidelines panel. Participation is completely free and open to all.
Assessment of Needs
Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV through case-based learning.
Learning Objectives
After participating in the activity, learners will be able to:
- Describe the latest recommendations for managing HIV in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
- Initiate and monitor HIV prevention intervention strategies, including the use of postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
- Describe the most current data on currently available and newly available antiretroviral drugs and approaches
- Initiate antiretroviral therapy in the context of an acute OI
- Screen for substance use disorders in HIV prevention and treatment settings
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.
Registration
Who Should Attend
This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for patients with HIV infection
Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Thursday, December 12, 2024, 3:00 PM (ET).
For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.
Continuing Education Credits
CME Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nursing Credits
Educational Review Systems is an approved approver of continuing nursing education by the ASNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 4 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.
This program is approved for 4.0 hours of pharmacotherapy credit.
Pharmacy Credits
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 4 contact hours (0.4 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-24-379-L02-P
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
PLATINUM SUPPORTERS
Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare
Frequently Asked Questions
View our list of FAQs about attending an activity.
Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.